Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

NCT07226999 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07226999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07226999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
Lead sponsor
Pfizer
Phase
Phase 2/3
Overall status
Recruiting
Start date
December 9, 2025
Completion date
March 11, 2034
Enrollment
550 (estimated)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer (sclc)